Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-06-15

AUTHORS

Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda

ABSTRACT

BackgroundFatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect. Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naïve and sulfonylurea-treated patients with type 2 diabetes mellitus. Anagliptin, another DPP-4 inhibitor, was shown to decrease low-density lipoprotein cholesterol (LDL-C) level to a greater extent than that by sitagliptin in the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial.Aim and methodsAs a sub-analysis study using data obtained from the REASON trial, we investigated the effects of treatment with anagliptin (n = 148, male/female: 89/59) and treatment with sitagliptin (n = 159, male/female: 93/66) for 52 weeks on FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular events who were receiving statin therapy.ResultsThe DPP-4 inhibitor had been administered in 82% of the patients in the anagliptin group and 81% of the patients in sitagliptin group prior to randomization. Serum FABP4 level was significantly decreased by 7.9% by treatment with anagliptin (P = 0.049) and was not significantly decreased by treatment with sitagliptin (P = 0.660). Change in FABP4 level was independently associated with basal FABP4 level and changes in waist circumference and creatinine after adjustment of age, sex and the treatment group.ConclusionAnagliptin decreases serum FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus and dyslipidemia who are on statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. Registered January 5, 2015, https://clinicaltrials.gov/ct2/show/NCT02330406 More... »

PAGES

89

References to SciGraph publications

  • 2014-08-21. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population in CARDIOVASCULAR DIABETOLOGY
  • 2016-01-12. Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters in LIPIDS IN HEALTH AND DISEASE
  • 2019-06-12. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial in SCIENTIFIC REPORTS
  • 2015-09-29. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes in CARDIOVASCULAR DIABETOLOGY
  • 2008-06. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets in NATURE REVIEWS DRUG DISCOVERY
  • 2015-02-12. Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension in HYPERTENSION RESEARCH
  • 2007-06-06. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 in NATURE
  • 2018-06-23. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study in CARDIOVASCULAR DIABETOLOGY
  • 2001-06. Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis in NATURE MEDICINE
  • 2019-06-24. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice in CARDIOVASCULAR DIABETOLOGY
  • 2019-11-16. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial in CARDIOVASCULAR DIABETOLOGY
  • 2018-02-12. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial in CARDIOVASCULAR DRUGS AND THERAPY
  • Journal

    TITLE

    Cardiovascular Diabetology

    ISSUE

    1

    VOLUME

    19

    Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12933-020-01061-0

    DOI

    http://dx.doi.org/10.1186/s12933-020-01061-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1128490671

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/32539832


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Glucose", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cardiovascular Diseases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholesterol, LDL", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus, Type 2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dipeptidyl-Peptidase IV Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Down-Regulation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dyslipidemias", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fatty Acid-Binding Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glycated Hemoglobin A", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pyrimidines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Assessment", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.263171.0", 
              "name": [
                "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Furuhashi", 
            "givenName": "Masato", 
            "id": "sg:person.0677037526.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677037526.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakuma", 
            "givenName": "Ichiro", 
            "id": "sg:person.01353136535.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353136535.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272264.7", 
              "name": [
                "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Morimoto", 
            "givenName": "Takeshi", 
            "id": "sg:person.011273662612.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.263171.0", 
              "name": [
                "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Higashiura", 
            "givenName": "Yukimura", 
            "id": "sg:person.01234613102.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234613102.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.263171.0", 
              "name": [
                "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakai", 
            "givenName": "Akiko", 
            "id": "sg:person.012106562053.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012106562053.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.263171.0", 
              "name": [
                "Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matsumoto", 
            "givenName": "Megumi", 
            "id": "sg:person.01161170333.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161170333.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan", 
              "id": "http://www.grid.ac/institutes/grid.272264.7", 
              "name": [
                "Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sakuma", 
            "givenName": "Mio", 
            "id": "sg:person.01041233531.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411582.b", 
              "name": [
                "Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shimabukuro", 
            "givenName": "Michio", 
            "id": "sg:person.01233731752.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nomiyama", 
            "givenName": "Takashi", 
            "id": "sg:person.01255040512.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan", 
              "id": "http://www.grid.ac/institutes/grid.460111.3", 
              "name": [
                "Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Arasaki", 
            "givenName": "Osamu", 
            "id": "sg:person.0611455170.93", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiovascular Medicine, Saga University, Saga, Japan", 
              "id": "http://www.grid.ac/institutes/grid.412339.e", 
              "name": [
                "Department of Cardiovascular Medicine, Saga University, Saga, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Node", 
            "givenName": "Koichi", 
            "id": "sg:person.01100453460.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan", 
              "id": "http://www.grid.ac/institutes/grid.267625.2", 
              "name": [
                "Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ueda", 
            "givenName": "Shinichiro", 
            "id": "sg:person.012353001702.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature05844", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028763891", 
              "https://doi.org/10.1038/nature05844"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12944-016-0177-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035678173", 
              "https://doi.org/10.1186/s12944-016-0177-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/hr.2015.2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029093540", 
              "https://doi.org/10.1038/hr.2015.2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12933-015-0294-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052199008", 
              "https://doi.org/10.1186/s12933-015-0294-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/89076", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011575439", 
              "https://doi.org/10.1038/89076"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-019-44885-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1117069698", 
              "https://doi.org/10.1038/s41598-019-44885-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10557-018-6776-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100981423", 
              "https://doi.org/10.1007/s10557-018-6776-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12933-014-0126-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047961127", 
              "https://doi.org/10.1186/s12933-014-0126-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12933-019-0965-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1122658455", 
              "https://doi.org/10.1186/s12933-019-0965-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2589", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048860342", 
              "https://doi.org/10.1038/nrd2589"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12933-018-0737-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1105087583", 
              "https://doi.org/10.1186/s12933-018-0737-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12933-019-0886-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1117477002", 
              "https://doi.org/10.1186/s12933-019-0886-1"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-06-15", 
        "datePublishedReg": "2020-06-15", 
        "description": "BackgroundFatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect. Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-na\u00efve and sulfonylurea-treated patients with type 2 diabetes mellitus. Anagliptin, another DPP-4 inhibitor, was shown to decrease low-density lipoprotein cholesterol (LDL-C) level to a greater extent than that by sitagliptin in the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial.Aim and methodsAs a sub-analysis study using data obtained from the REASON trial, we investigated the effects of treatment with anagliptin (n\u2009=\u2009148, male/female: 89/59) and treatment with sitagliptin (n\u2009=\u2009159, male/female: 93/66) for 52\u00a0weeks on FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular events who were receiving statin therapy.ResultsThe DPP-4 inhibitor had been administered in 82% of the patients in the anagliptin group and 81% of the patients in sitagliptin group prior to randomization. Serum FABP4 level was significantly decreased by 7.9% by treatment with anagliptin (P\u2009=\u20090.049) and was not significantly decreased by treatment with sitagliptin (P\u2009=\u20090.660). Change in FABP4 level was independently associated with basal FABP4 level and changes in waist circumference and creatinine after adjustment of age, sex and the treatment group.ConclusionAnagliptin decreases serum FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus and dyslipidemia who are on statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. Registered January 5, 2015, https://clinicaltrials.gov/ct2/show/NCT02330406", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12933-020-01061-0", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.9199901", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1031021", 
            "issn": [
              "1475-2840"
            ], 
            "name": "Cardiovascular Diabetology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "19"
          }
        ], 
        "keywords": [
          "type 2 diabetes mellitus", 
          "DPP-4 inhibitors", 
          "FABP4 concentration", 
          "diabetes mellitus", 
          "statin therapy", 
          "FABP4 levels", 
          "high risk", 
          "low-density lipoprotein cholesterol levels", 
          "low-density lipoprotein cholesterol", 
          "dipeptidyl peptidase-4 inhibitors", 
          "sulfonylurea-treated patients", 
          "serum FABP4 levels", 
          "serum FABP4 concentrations", 
          "drug class effect", 
          "lipoprotein cholesterol levels", 
          "peptidase-4 inhibitors", 
          "adjustment of age", 
          "effect of treatment", 
          "REASON trial", 
          "anagliptin group", 
          "cardiovascular events", 
          "sitagliptin group", 
          "lipoprotein cholesterol", 
          "Diabetes (ACCORD) trial", 
          "waist circumference", 
          "novel adipokine", 
          "drug-na\u00efve", 
          "insulin resistance", 
          "cholesterol levels", 
          "cardiovascular disease", 
          "antidiabetic drugs", 
          "treatment groups", 
          "drug effects", 
          "patients", 
          "mellitus", 
          "sitagliptin", 
          "anagliptin", 
          "Randomized Evaluation", 
          "class effect", 
          "therapy", 
          "protein 4", 
          "treatment", 
          "inhibitors", 
          "trials", 
          "drugs", 
          "risk", 
          "group", 
          "dyslipidemia", 
          "adipokines", 
          "obesity", 
          "atherosclerosis", 
          "creatinine", 
          "levels", 
          "LDL", 
          "MethodsA", 
          "disease", 
          "cholesterol", 
          "weeks", 
          "circumference", 
          "hemoglobin", 
          "age", 
          "greater extent", 
          "sex", 
          "randomization", 
          "concentration", 
          "effect", 
          "changes", 
          "adjustment", 
          "evaluation", 
          "study", 
          "events", 
          "resistance", 
          "extent", 
          "data", 
          "distinct structures", 
          "class", 
          "structure"
        ], 
        "name": "Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy", 
        "pagination": "89", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1128490671"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12933-020-01061-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "32539832"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12933-020-01061-0", 
          "https://app.dimensions.ai/details/publication/pub.1128490671"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:04", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_859.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12933-020-01061-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12933-020-01061-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12933-020-01061-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12933-020-01061-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12933-020-01061-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    368 TRIPLES      21 PREDICATES      135 URIs      115 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12933-020-01061-0 schema:about N1d5c57dff7b84d78942547f85e7ba445
    2 N34a959e6acb749468c4bbcd926f239cf
    3 N3decc612df1f464dadb05ef6fdbe9000
    4 N3e4e6f1d0bf3476eb5df7a865e04698b
    5 N458d5208f5c746b6ad8d7627c3dfc2b8
    6 N4c802acc61b44656831230f5b99fd16b
    7 N571ba86df40e4ca6bfc9189f24c604e9
    8 N67e5147860814a14a6e9cae1912ac860
    9 N737e10c2c6e948139832d577183a05d7
    10 N75d0a88ba7ff42c08d2acacfb3501cd6
    11 N78e7c8683bf8473ba21dc4e4f4532e19
    12 N7fc8338b35b04ea0aaf961e868f81ba3
    13 N8020377387ab4b1e8249840818ab6e14
    14 N8e24a3b06a62497dac92161634377827
    15 Nc7ad1d7ca0dc477c8dee56e1e1d6d9c6
    16 Ne9032bab32e64748a029d7fd2fd8b8f9
    17 Nea7ce40cd19c4872a312206799055238
    18 Nef23b94475244caab5b9761318dda339
    19 Nef2feb58fa844e07b7a77346992a40c0
    20 Nf32a43b4884c4a09ba4a4fc99e886add
    21 Nf3cab70a74b04d398c8ec920f773ca53
    22 anzsrc-for:11
    23 anzsrc-for:1103
    24 schema:author Nf49663ef5da34b38b2283cf818eda140
    25 schema:citation sg:pub.10.1007/s10557-018-6776-z
    26 sg:pub.10.1038/89076
    27 sg:pub.10.1038/hr.2015.2
    28 sg:pub.10.1038/nature05844
    29 sg:pub.10.1038/nrd2589
    30 sg:pub.10.1038/s41598-019-44885-x
    31 sg:pub.10.1186/s12933-014-0126-7
    32 sg:pub.10.1186/s12933-015-0294-0
    33 sg:pub.10.1186/s12933-018-0737-5
    34 sg:pub.10.1186/s12933-019-0886-1
    35 sg:pub.10.1186/s12933-019-0965-3
    36 sg:pub.10.1186/s12944-016-0177-8
    37 schema:datePublished 2020-06-15
    38 schema:datePublishedReg 2020-06-15
    39 schema:description BackgroundFatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect. Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naïve and sulfonylurea-treated patients with type 2 diabetes mellitus. Anagliptin, another DPP-4 inhibitor, was shown to decrease low-density lipoprotein cholesterol (LDL-C) level to a greater extent than that by sitagliptin in the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial.Aim and methodsAs a sub-analysis study using data obtained from the REASON trial, we investigated the effects of treatment with anagliptin (n = 148, male/female: 89/59) and treatment with sitagliptin (n = 159, male/female: 93/66) for 52 weeks on FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular events who were receiving statin therapy.ResultsThe DPP-4 inhibitor had been administered in 82% of the patients in the anagliptin group and 81% of the patients in sitagliptin group prior to randomization. Serum FABP4 level was significantly decreased by 7.9% by treatment with anagliptin (P = 0.049) and was not significantly decreased by treatment with sitagliptin (P = 0.660). Change in FABP4 level was independently associated with basal FABP4 level and changes in waist circumference and creatinine after adjustment of age, sex and the treatment group.ConclusionAnagliptin decreases serum FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus and dyslipidemia who are on statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. Registered January 5, 2015, https://clinicaltrials.gov/ct2/show/NCT02330406
    40 schema:genre article
    41 schema:isAccessibleForFree true
    42 schema:isPartOf N16c4e817f0b04a5c9f9281f8d32c28c8
    43 Nebf2b2eb1c474b44bebcd90abc86b402
    44 sg:journal.1031021
    45 schema:keywords DPP-4 inhibitors
    46 Diabetes (ACCORD) trial
    47 FABP4 concentration
    48 FABP4 levels
    49 LDL
    50 MethodsA
    51 REASON trial
    52 Randomized Evaluation
    53 adipokines
    54 adjustment
    55 adjustment of age
    56 age
    57 anagliptin
    58 anagliptin group
    59 antidiabetic drugs
    60 atherosclerosis
    61 cardiovascular disease
    62 cardiovascular events
    63 changes
    64 cholesterol
    65 cholesterol levels
    66 circumference
    67 class
    68 class effect
    69 concentration
    70 creatinine
    71 data
    72 diabetes mellitus
    73 dipeptidyl peptidase-4 inhibitors
    74 disease
    75 distinct structures
    76 drug class effect
    77 drug effects
    78 drug-naïve
    79 drugs
    80 dyslipidemia
    81 effect
    82 effect of treatment
    83 evaluation
    84 events
    85 extent
    86 greater extent
    87 group
    88 hemoglobin
    89 high risk
    90 inhibitors
    91 insulin resistance
    92 levels
    93 lipoprotein cholesterol
    94 lipoprotein cholesterol levels
    95 low-density lipoprotein cholesterol
    96 low-density lipoprotein cholesterol levels
    97 mellitus
    98 novel adipokine
    99 obesity
    100 patients
    101 peptidase-4 inhibitors
    102 protein 4
    103 randomization
    104 resistance
    105 risk
    106 serum FABP4 concentrations
    107 serum FABP4 levels
    108 sex
    109 sitagliptin
    110 sitagliptin group
    111 statin therapy
    112 structure
    113 study
    114 sulfonylurea-treated patients
    115 therapy
    116 treatment
    117 treatment groups
    118 trials
    119 type 2 diabetes mellitus
    120 waist circumference
    121 weeks
    122 schema:name Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
    123 schema:pagination 89
    124 schema:productId N087560a6d420495bb87e6c97d6c40994
    125 N11ba1e25f4d84fd6b8965bd272654b81
    126 N3b5bdb34858f43bb8a61ea94ef88d683
    127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128490671
    128 https://doi.org/10.1186/s12933-020-01061-0
    129 schema:sdDatePublished 2022-09-02T16:04
    130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    131 schema:sdPublisher N9367b5316a4c434cbe873e9ce776a3c5
    132 schema:url https://doi.org/10.1186/s12933-020-01061-0
    133 sgo:license sg:explorer/license/
    134 sgo:sdDataset articles
    135 rdf:type schema:ScholarlyArticle
    136 N087560a6d420495bb87e6c97d6c40994 schema:name pubmed_id
    137 schema:value 32539832
    138 rdf:type schema:PropertyValue
    139 N11ba1e25f4d84fd6b8965bd272654b81 schema:name doi
    140 schema:value 10.1186/s12933-020-01061-0
    141 rdf:type schema:PropertyValue
    142 N16c4e817f0b04a5c9f9281f8d32c28c8 schema:volumeNumber 19
    143 rdf:type schema:PublicationVolume
    144 N1d5c57dff7b84d78942547f85e7ba445 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Blood Glucose
    146 rdf:type schema:DefinedTerm
    147 N34a959e6acb749468c4bbcd926f239cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Aged
    149 rdf:type schema:DefinedTerm
    150 N3ac0421340dd420badbb83e65b8d4da6 rdf:first sg:person.012353001702.96
    151 rdf:rest rdf:nil
    152 N3b5bdb34858f43bb8a61ea94ef88d683 schema:name dimensions_id
    153 schema:value pub.1128490671
    154 rdf:type schema:PropertyValue
    155 N3decc612df1f464dadb05ef6fdbe9000 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Risk Assessment
    157 rdf:type schema:DefinedTerm
    158 N3e4e6f1d0bf3476eb5df7a865e04698b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Female
    160 rdf:type schema:DefinedTerm
    161 N458d5208f5c746b6ad8d7627c3dfc2b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Time Factors
    163 rdf:type schema:DefinedTerm
    164 N4c802acc61b44656831230f5b99fd16b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Cardiovascular Diseases
    166 rdf:type schema:DefinedTerm
    167 N571ba86df40e4ca6bfc9189f24c604e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Diabetes Mellitus, Type 2
    169 rdf:type schema:DefinedTerm
    170 N67e5147860814a14a6e9cae1912ac860 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Pyrimidines
    172 rdf:type schema:DefinedTerm
    173 N737e10c2c6e948139832d577183a05d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Cholesterol, LDL
    175 rdf:type schema:DefinedTerm
    176 N75d0a88ba7ff42c08d2acacfb3501cd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Biomarkers
    178 rdf:type schema:DefinedTerm
    179 N78e7c8683bf8473ba21dc4e4f4532e19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Male
    181 rdf:type schema:DefinedTerm
    182 N7d4dbabc25d547a6808582a389cd5816 rdf:first sg:person.01234613102.25
    183 rdf:rest Nefe0312ebdf444fe8f0f6283b80659d5
    184 N7fc8338b35b04ea0aaf961e868f81ba3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Humans
    186 rdf:type schema:DefinedTerm
    187 N8020377387ab4b1e8249840818ab6e14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Glycated Hemoglobin A
    189 rdf:type schema:DefinedTerm
    190 N8b3b22ee02724cca85c982ee7d449c21 rdf:first sg:person.01255040512.80
    191 rdf:rest N9c7221c03c20414ea226a391dbe2e9cc
    192 N8e24a3b06a62497dac92161634377827 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
    194 rdf:type schema:DefinedTerm
    195 N9367b5316a4c434cbe873e9ce776a3c5 schema:name Springer Nature - SN SciGraph project
    196 rdf:type schema:Organization
    197 N9c7221c03c20414ea226a391dbe2e9cc rdf:first sg:person.0611455170.93
    198 rdf:rest Nb0f5ba3b6c324fa48f9d4197a2a9038d
    199 Na4f1cda065ad485280564f8e00667d71 rdf:first sg:person.01161170333.74
    200 rdf:rest Neaf49f4100b24e3ba9e44c5648cb3eaf
    201 Nb0f5ba3b6c324fa48f9d4197a2a9038d rdf:first sg:person.01100453460.13
    202 rdf:rest N3ac0421340dd420badbb83e65b8d4da6
    203 Nc7ad1d7ca0dc477c8dee56e1e1d6d9c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name Fatty Acid-Binding Proteins
    205 rdf:type schema:DefinedTerm
    206 Ncabcea2b246c4180a3dc87290f8fd83c rdf:first sg:person.01233731752.49
    207 rdf:rest N8b3b22ee02724cca85c982ee7d449c21
    208 Ne9032bab32e64748a029d7fd2fd8b8f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Risk Factors
    210 rdf:type schema:DefinedTerm
    211 Nea7ce40cd19c4872a312206799055238 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Down-Regulation
    213 rdf:type schema:DefinedTerm
    214 Neaf49f4100b24e3ba9e44c5648cb3eaf rdf:first sg:person.01041233531.06
    215 rdf:rest Ncabcea2b246c4180a3dc87290f8fd83c
    216 Neb30e749859847e583dd2b03d9b5a6ec rdf:first sg:person.011273662612.03
    217 rdf:rest N7d4dbabc25d547a6808582a389cd5816
    218 Nebf2b2eb1c474b44bebcd90abc86b402 schema:issueNumber 1
    219 rdf:type schema:PublicationIssue
    220 Nec80dfc4570b47ce9566241a61bba1bc rdf:first sg:person.01353136535.75
    221 rdf:rest Neb30e749859847e583dd2b03d9b5a6ec
    222 Nef23b94475244caab5b9761318dda339 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    223 schema:name Middle Aged
    224 rdf:type schema:DefinedTerm
    225 Nef2feb58fa844e07b7a77346992a40c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    226 schema:name Dipeptidyl-Peptidase IV Inhibitors
    227 rdf:type schema:DefinedTerm
    228 Nefe0312ebdf444fe8f0f6283b80659d5 rdf:first sg:person.012106562053.58
    229 rdf:rest Na4f1cda065ad485280564f8e00667d71
    230 Nf32a43b4884c4a09ba4a4fc99e886add schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    231 schema:name Dyslipidemias
    232 rdf:type schema:DefinedTerm
    233 Nf3cab70a74b04d398c8ec920f773ca53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    234 schema:name Treatment Outcome
    235 rdf:type schema:DefinedTerm
    236 Nf49663ef5da34b38b2283cf818eda140 rdf:first sg:person.0677037526.56
    237 rdf:rest Nec80dfc4570b47ce9566241a61bba1bc
    238 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    239 schema:name Medical and Health Sciences
    240 rdf:type schema:DefinedTerm
    241 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    242 schema:name Clinical Sciences
    243 rdf:type schema:DefinedTerm
    244 sg:grant.9199901 http://pending.schema.org/fundedItem sg:pub.10.1186/s12933-020-01061-0
    245 rdf:type schema:MonetaryGrant
    246 sg:journal.1031021 schema:issn 1475-2840
    247 schema:name Cardiovascular Diabetology
    248 schema:publisher Springer Nature
    249 rdf:type schema:Periodical
    250 sg:person.01041233531.06 schema:affiliation grid-institutes:grid.272264.7
    251 schema:familyName Sakuma
    252 schema:givenName Mio
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041233531.06
    254 rdf:type schema:Person
    255 sg:person.01100453460.13 schema:affiliation grid-institutes:grid.412339.e
    256 schema:familyName Node
    257 schema:givenName Koichi
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100453460.13
    259 rdf:type schema:Person
    260 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
    261 schema:familyName Morimoto
    262 schema:givenName Takeshi
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
    264 rdf:type schema:Person
    265 sg:person.01161170333.74 schema:affiliation grid-institutes:grid.263171.0
    266 schema:familyName Matsumoto
    267 schema:givenName Megumi
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161170333.74
    269 rdf:type schema:Person
    270 sg:person.012106562053.58 schema:affiliation grid-institutes:grid.263171.0
    271 schema:familyName Sakai
    272 schema:givenName Akiko
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012106562053.58
    274 rdf:type schema:Person
    275 sg:person.01233731752.49 schema:affiliation grid-institutes:grid.411582.b
    276 schema:familyName Shimabukuro
    277 schema:givenName Michio
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233731752.49
    279 rdf:type schema:Person
    280 sg:person.01234613102.25 schema:affiliation grid-institutes:grid.263171.0
    281 schema:familyName Higashiura
    282 schema:givenName Yukimura
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234613102.25
    284 rdf:type schema:Person
    285 sg:person.012353001702.96 schema:affiliation grid-institutes:grid.267625.2
    286 schema:familyName Ueda
    287 schema:givenName Shinichiro
    288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012353001702.96
    289 rdf:type schema:Person
    290 sg:person.01255040512.80 schema:affiliation grid-institutes:None
    291 schema:familyName Nomiyama
    292 schema:givenName Takashi
    293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255040512.80
    294 rdf:type schema:Person
    295 sg:person.01353136535.75 schema:affiliation grid-institutes:None
    296 schema:familyName Sakuma
    297 schema:givenName Ichiro
    298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353136535.75
    299 rdf:type schema:Person
    300 sg:person.0611455170.93 schema:affiliation grid-institutes:grid.460111.3
    301 schema:familyName Arasaki
    302 schema:givenName Osamu
    303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611455170.93
    304 rdf:type schema:Person
    305 sg:person.0677037526.56 schema:affiliation grid-institutes:grid.263171.0
    306 schema:familyName Furuhashi
    307 schema:givenName Masato
    308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677037526.56
    309 rdf:type schema:Person
    310 sg:pub.10.1007/s10557-018-6776-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1100981423
    311 https://doi.org/10.1007/s10557-018-6776-z
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1038/89076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011575439
    314 https://doi.org/10.1038/89076
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1038/hr.2015.2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029093540
    317 https://doi.org/10.1038/hr.2015.2
    318 rdf:type schema:CreativeWork
    319 sg:pub.10.1038/nature05844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028763891
    320 https://doi.org/10.1038/nature05844
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.1038/nrd2589 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048860342
    323 https://doi.org/10.1038/nrd2589
    324 rdf:type schema:CreativeWork
    325 sg:pub.10.1038/s41598-019-44885-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1117069698
    326 https://doi.org/10.1038/s41598-019-44885-x
    327 rdf:type schema:CreativeWork
    328 sg:pub.10.1186/s12933-014-0126-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047961127
    329 https://doi.org/10.1186/s12933-014-0126-7
    330 rdf:type schema:CreativeWork
    331 sg:pub.10.1186/s12933-015-0294-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052199008
    332 https://doi.org/10.1186/s12933-015-0294-0
    333 rdf:type schema:CreativeWork
    334 sg:pub.10.1186/s12933-018-0737-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105087583
    335 https://doi.org/10.1186/s12933-018-0737-5
    336 rdf:type schema:CreativeWork
    337 sg:pub.10.1186/s12933-019-0886-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117477002
    338 https://doi.org/10.1186/s12933-019-0886-1
    339 rdf:type schema:CreativeWork
    340 sg:pub.10.1186/s12933-019-0965-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122658455
    341 https://doi.org/10.1186/s12933-019-0965-3
    342 rdf:type schema:CreativeWork
    343 sg:pub.10.1186/s12944-016-0177-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035678173
    344 https://doi.org/10.1186/s12944-016-0177-8
    345 rdf:type schema:CreativeWork
    346 grid-institutes:None schema:alternateName Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan
    347 Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan
    348 schema:name Caress Sapporo Hokko Memorial Clinic, Sapporo, Japan
    349 Department of Diabetes, Metabolism and Endocrinology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan
    350 rdf:type schema:Organization
    351 grid-institutes:grid.263171.0 schema:alternateName Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan
    352 schema:name Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, South 1, West 16, 060-8543, Sapporo, Japan
    353 rdf:type schema:Organization
    354 grid-institutes:grid.267625.2 schema:alternateName Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
    355 schema:name Department of Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Japan
    356 rdf:type schema:Organization
    357 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
    358 schema:name Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
    359 rdf:type schema:Organization
    360 grid-institutes:grid.411582.b schema:alternateName Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
    361 schema:name Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan
    362 rdf:type schema:Organization
    363 grid-institutes:grid.412339.e schema:alternateName Department of Cardiovascular Medicine, Saga University, Saga, Japan
    364 schema:name Department of Cardiovascular Medicine, Saga University, Saga, Japan
    365 rdf:type schema:Organization
    366 grid-institutes:grid.460111.3 schema:alternateName Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
    367 schema:name Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Japan
    368 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...